Next Phase Newsletter

The corporate venture capital arm of a large tech company is currently seeking to invest the in intersection of software and biology. The fund invests in companies at a variety of developmental stages and investments therefore vary widely, but typically range from $1-10m of equity. The firm is looking for opportunities globally.

Within the medical technology sector, the firm is interested in the intersection between communication and health, and particularly in technologies that improve delivery of patient care and make care more cost-effective. Areas of focus include traditional healthcare IT (particularly data and communications in a hospital setting), personalized medicine, mobile health technology (including connected medical devices, consumer apps, and patient monitoring technologies that can be used both inside and outside hospitals), and genomic platforms that provide actionable information for patient care (technologies used purely for gene sequencing are not of interest). While it is not an area of primary focus, connected lab equipment may also be of interest.

The firm invests only in privately-held companies. The firm backs innovative, creative entrepreneurs with expertise in their fields, and who are developing solutions that will have an impact on the health marketplace.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A life sciences venture capital firm based in Canada with an additional office in the US is currently investing from two new funds totaling approximately $165 million of new capital under management. The firm typically makes initial investments ranging from $1-$5 million of equity and looks to invest $8-$12 million over the lifetime of the investment. The firm plans to make 4-6 investments over the next 12 months and evaluates opportunities throughout the US and Canada.

The firm is currently looking for companies developing Therapeutics, Medical Devices, and Healthcare IT. The firm has a special interest in immunology, inflammation, cell therapy, vaccines and protein based therapies, although the firm will also consider other small molecule and biologics therapies in other areas. The firm is looking for companies with assets in phase I and II of clinical trials that have at least some human proof of concept with either early human efficacy signs or very strong animal data coupled with human safety data. In the medical devices space the firm is opportunistic in term of device type but also requires some in-human data to be evaluated for investment. In the past the firm has invested in devices for cardiology, obesity, medical imaging, and others. In the healthcare IT space the firm is most interested in subsectors of mobile health, patient monitoring and consumer based technologies, particularly in products that help make healthcare systems more efficient.

The firm is looking to invest in companies that are pre-revenue located throughout the United States and Canada. The firm does not look to take an active role on the management team but does look to take a board seat.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The operational and investment arm of a family office is looking to make equity investments into early stage companies and small mid-market growth companies ranging from $.5 to $1 million. The firm is very open to syndication particularly with early stage deals and is capable of providing additional capital in follow on rounds when appropriate. The firm prefers to invest in companies located in the eastern United States and looks to make approximately 1-2 new investments per year.

The firm is looking for companies in the Medical Technology and Diagnostics space. Within these areas the firm is looking for 510k devices that are more technically based with a particular interest in hospital equipment and professional diagnostics. The firm is not interest in devices where the final consumer is the patient. The firm is looking to devices that improve the standard of care and is willing to invest in companies at all phases of development. The firm is generally open to all indications.

The firm looks for experienced management teams and looks to take a board seat following investment. The firm is willing to work with companies that have incomplete management teams and is looking for privately held companies.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

The corporate venture capital arm of a large pharmaceutical company is currently looking to make equity investments into early stage life science companies. The firm has the ability to allocate up to $10 million dollars per company, generally in milestone driven tranches. The firm is able to invest in companies from around the globe and is actively seeking new investment opportunities.

The firm is looking for early stage companies working with therapeutics and companion diagnostics. The firm is open to review both small molecules and biologics as well as companies working with single assets or platform technologies. The firm seeks to invest in indication areas including Immunology, Oncology, Immunoncology, MS, and Fertility. The firm generally looks for companies with assets that are pre-clinical or in Phase 1 clinical trials.

The firm is looking for privately held companies with experienced management teams. The firm looks to take an active role following investing generally taking at least a board seat. The firm is willing to both lead rounds and co-invest as a member of a syndicate。

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A biotechnology-focused equity hedge fund based in Western US is looking to invest in therapeutics space. The investment size can vary greatly and the fund is very flexible depending on each company’s needs. The fund is geographically agnostic and looks to invest globally.

The firm is highly interested in biotech therapeutics. The fund is extremely opportunistic in terms of subsectors and indications and will consider companies at all stages of development. The fund recently invested in a European-based company developing small molecule therapeutics for CNS diseases and a US-based company developing therapeutics for oncology.

The firm seeks a company with a strong and experienced management team or technical experts in the relevant technology. The fund will require either a board seat or observer status.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A venture capital firm based in the Western United States is currently investing out of its 2nd million dollar fund. The firm makes primarily equity investments ranging from $50,000 to $5 million over the lifetime of the investment. The firm prefers to invest in companies located in the United States although they are also open to review internationally based opportunities and are currently working with a few companies in Israel. The firm plans to make approximately 2 new investments over the next 6-9 months.

The firm is looking for seed and venture stage medical and diagnostic device companies. In these areas the firm is most interested in single use devices capable of delivering a therapy, and in indications such as cancer, cardiovascular and neurological diseases, orthopedic problems, respiratory conditions, and gastrointestinal disorders. While this is the firm’s primary focus, they remain open minded to other types of devices and indications as well.

The firm looks for professionalism in a firms management teams and is willing to work with firms that do not yet have a complete management team in place. The firm does not always look to take a board seat into companies however the firm does look to add value by developing strategic corporate partnerships in Japan when appropriate.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com

A global private equity firm with bases in Hong Kong and the United States is primarily focused on healthcare investments with a particular interest in the life science space. The firm looks to make allocations ranging from $250,000 as the first round in a tranched financing structure to $20 million over the lifetime of the investment and depending on the financial needs of the company. The firm is actively seeking new investments and is open to review opportunities from around the globe.

Within the life science space, the firm is interested in therapeutics, medical devices, and diagnostics. The firm is currently most interested in companies with some clinical data; however they are open to reviewing pre-clinical stage opportunities as well. The firm is open to biosimilar and repurposed assets, and has a preference for platform technologies but is also open to considering single asset opportunities. The firm is open to review all classes of medical devices and diagnostics. The firm is entirely open in terms of indication.

The firm is open to investing in both private and public companies and is currently very interested in making cross over investments. The firm is also very interested in companies that have a plan or ability to enter the Chinese market as the firm can add significant value with this strategy. The firm is open to acting as both a lead and co-investor.

If you are interested in more information about this investor and other investors tracked by LSN, please email mandates@lifesciencenation.com